Earnings ·
Myriad Genetics reported second quarter 2026 revenue of $190.7 million, an 11% year-over-year decline driven by a 9%…
MYGNMyriad Genetics Inc
Myriad Genetics reported second quarter 2026 revenue of $190.7 million, an 11% year-over-year decline driven by a 9% drop in average revenue per test and a 1% volume decrease. The company announced revised full-year 2026 financial guidance, lowering the revenue range to $770–$790 million from previous estimates and suspending Adjusted EBITDA guidance due to lower Prenatal Health volumes and payer friction pressures. Management initiated a strategic review and an efficiency program called Ascend, supported by a professional services firm, while continuing to expand its Cancer Care Continuum portfolio with new AI-enabled tests and coverage submissions. Myriad Genetics operates in the molecular diagnostic testing and precision medicine industry.